Article Information
History
- October 7, 2021.
Article Versions
- Version 1 (October 5, 2021 - 07:37).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Jocelyn Dupuis, MD, PhDa,b,*,
- Pierre Laurin, MSc Pharmc,
- Jean-Claude Tardif, MDa,b,
- Leslie Hausermann, PhDa,
- Camille Rosa, MScd,
- Marie-Claude Guertin, PhDd,
- Karen Thibaudeau, PhDc,
- Lyne Gagnon, PhDc,
- Frank Cesari, BScc,
- Martin Robitaille, PhDc and
- John E. Moran, MDc
- aMontreal Heart Institute Research Center, Montreal, Quebec, Canada
- bDepartment of Medicine of Université de Montréal, Montreal, Quebec, Canada
- cIngenew Pharmaceuticals, Montreal, Quebec, Canada
- dMontreal Health Innovations Coordination Center, Montreal, Quebec, Canada
- ↵*Corresponding author: Jocelyn Dupuis MD, PhD, Research Center, Montreal Heart Institute, 5000 Belanger Street, Montreal, Qc H1T 1C8, Canada. Tel. 514-376-3330. Fax 514-376-1355 E-mail: dupuisj{at}icloud.com
Posted October 07, 2021.
Fourteen-days Evolution of COVID-19 Symptoms During the Third Wave in Non-vaccinated Subjects and Effects of Hesperidin Therapy: A randomized, double-blinded, placebo-controlled study
